Dizal Pharma
Dizal Pharma (Dizal (Jiangsu) Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines in oncology and immunology. Originating in 2017 from research capabilities established in China, the company operates research and development across Shanghai and Wuxi (Jiangsu), China, and is listed on the Shanghai Stock Exchange STAR Market (ticker 688192). Dizal's most advanced programs include sunvozertinib (DZD9008), an oral EGFR exon 20 insertion inhibitor for non-small cell lung cancer marketed as Zegfrovy, and golidocitinib (DZD4205), a selective JAK1 inhibitor developed for relapsed/refractory peripheral T-cell lymphoma. Dizal Pharma was surfaced in the API Evangelist network as a portfolio company of the venture firm HongShan (formerly Sequoia Capital China). As a pharmaceutical developer it publishes a corporate marketing and investor-facing website but does not expose a public developer platform, API program, or machine-readable API artifacts at this time; this profile captures the company identity for the network.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Dizal Pharma the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Dizal Pharma scores 8.1/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Dizal Pharma
Each block below is one kind of artifact we hold for Dizal Pharma. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Dizal Pharma — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 4
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/dizal-pharma · machine-readable index on apis.io